about
Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort.Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastasesClinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM studyEfficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma.Combined therapy with dabrafenib and trametinib in BRAF-mutated metastatic melanoma in a real-life setting: the INT Milan experience.Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125bIpilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy.Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programmeOutcome Evaluation of Patients with Limited Brain Metastasis From Malignant Melanoma, Treated with Surgery, Radiation Therapy, and Targeted Therapy.Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors.Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma.T-cell activation and maturation at tumor site associated with objective response to ipilimumab in metastatic melanomaInvestigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
P50
Q30828178-F4E21E3A-995E-4F0B-AC39-38E99F99731AQ33620317-60D3355A-8037-43B4-921D-CA6076F84D42Q33830941-834050A1-0BCE-455F-ABBD-DC657AAF5C75Q34656538-FC0EBA5F-27AB-415D-BB6B-62EA586D21D7Q36089197-35E36E66-81AB-4C9F-97B8-972A8F46BEBAQ36782461-D7EB57CF-D9F7-48B3-8007-D417F71F3F6FQ37681718-38DB8ABC-FC81-45AF-A7A9-B0CB9E9F736CQ37718203-8ED97D44-284E-4D8B-9665-68F7DB7292B3Q38376086-BA68B939-A48A-413D-8CE3-BB258516CFD2Q39009684-A82D95C8-92A9-41A7-908C-21B6BBD688C7Q42844316-DAF017A7-F93C-484D-AE65-F1E7DA4E8FB7Q50147228-9C67D2F8-5255-452A-8056-EBB288546A2DQ56898443-FAD6EAED-6EDA-4E5D-BDD6-A89214F6B5E4Q90431041-C161444B-E8E9-48BF-9491-BB151B68BC3F
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Lorenza Di Guardo
@ast
Lorenza Di Guardo
@en
Lorenza Di Guardo
@es
Lorenza Di Guardo
@nl
type
label
Lorenza Di Guardo
@ast
Lorenza Di Guardo
@en
Lorenza Di Guardo
@es
Lorenza Di Guardo
@nl
prefLabel
Lorenza Di Guardo
@ast
Lorenza Di Guardo
@en
Lorenza Di Guardo
@es
Lorenza Di Guardo
@nl
P106
P1153
35096015700
P31
P496
0000-0002-7297-319X